PI3K Delta Inhibitor Idelalisib (GS-1101) with Rituximab and/or Bendamustine for Relapsed/Refractory CLL


PI3K Delta Inhibitor Idelalisib (GS-1101) with Rituximab and/or Bendamustine for Relapsed/Refractory CLL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)
Coutre SE et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a Phase I study. Proc ASH 2012;Abstract 191.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.